Polymorphisms of Antioxidant Enzymes SOD2 (rs4880) and GPX1 (rs1050450) Are Associated with Bladder Cancer Risk or Its Aggressiveness.


Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
09 Jan 2023
Historique:
received: 05 11 2022
revised: 19 12 2022
accepted: 29 12 2022
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

Background and Objectives: Oxidative stress induced by increased reactive oxygen species (ROS) production plays an important role in carcinogenesis. The entire urinary tract is continuously exposed to numerous potentially mutagenic environmental agents which generate ROS during their biotransformation. In first line defense against free radicals, antioxidant enzymes superoxide dismutase (SOD2) and glutathione peroxidase (GPX1) both have essential roles. Altered enzyme activity and decreased ability of neutralizing free oxygen radicals as a consequence of genetic polymorphisms in genes encoding these two enzymes are well described so far. This study aimed to investigate the association of GPX1 (rs1050450) and SOD2 (rs4880) genetic variants with the urothelial bladder cancer (UBC) risk independently and in combination with smoking. Furthermore, we aimed to determine whether the UBC stage and pathological grade were influenced by GPX1 and SOD2 polymorphisms. Material and Methods: The study population included 330 patients with UBC (mean age 65 ± 10.3 years) and 227 respective controls (mean age 63.4 ± 7.9 years). Single nucleotide polymorphism (SNP) of GPX1 (rs1050450) was analyzed using the PCR-RFLP, while SOD2 (rs4880) SNP was analyzed using the q-PCR method. Results: Our results showed that UBC risk was significantly increased among carriers of at least one variant SOD2 Val allele compared to the SOD2 Ala16Ala homozygotes (OR = 1.55, p = 0.03). Moreover, this risk was even more pronounced in smokers with at least one variant SOD2 Val allele, since they have even 7.5 fold higher UBC risk (OR = 7.5, p < 0.001). Considering GPX1 polymorphism, we have not found an association with UBC risk. However, GPX1 genotypes distribution differed significantly according to the tumor stage (p ˂ 0.049) and pathohistological grade (p ˂ 0.018). Conclusion: We found that SOD2 genetic polymorphism is associated with the risk of UBC development independently and in combination with cigarette smoking. Furthermore, we showed that GPX1 genetic polymorphism is associated with the aggressiveness of the disease.

Identifiants

pubmed: 36676755
pii: medicina59010131
doi: 10.3390/medicina59010131
pmc: PMC9860962
pii:
doi:

Substances chimiques

Glutathione Peroxidase EC 1.11.1.9
Antioxidants 0
Glutathione Peroxidase GPX1 EC 1.11.1.9
Reactive Oxygen Species 0
Superoxide Dismutase EC 1.15.1.1
Free Radicals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
ID : 200110
Pays : United Kingdom
Organisme : Individual project of Serbian Academy of Science and Arts
ID : F32

Références

Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1581-6
pubmed: 17646272
Antioxidants (Basel). 2020 Apr 30;9(5):
pubmed: 32365852
Eur Urol Focus. 2015 Aug;1(1):17-27
pubmed: 28723350
Carcinogenesis. 2008 Dec;29(12):2335-40
pubmed: 18784358
Tumour Biol. 2014 Jan;35(1):759-64
pubmed: 24037914
Oncol Res. 2010;18(8):395-400
pubmed: 20441054
JAMA. 2011 Aug 17;306(7):737-45
pubmed: 21846855
Cancer Metab. 2014 Nov 28;2:17
pubmed: 25671107
Mol Biol Rep. 2013 Feb;40(2):1801-12
pubmed: 23073788
Breast Cancer Res Treat. 2010 Nov;124(2):425-31
pubmed: 20306294
J Laryngol Otol. 2013 Oct;127(10):997-1000
pubmed: 24074040
J Physiol Pharmacol. 2013 Aug;64(4):409-21
pubmed: 24101387
Cancer Res. 2000 Apr 15;60(8):2290-9
pubmed: 10786697
Toxicol Pathol. 2010 Jan;38(1):96-109
pubmed: 20019356
Int Urol Nephrol. 2009;41(1):63-70
pubmed: 18563616
Int J Clin Exp Med. 2015 Sep 15;8(9):14647-55
pubmed: 26628947
Eur J Epidemiol. 2016 Sep;31(9):811-51
pubmed: 27000312
Cancers (Basel). 2022 May 23;14(10):
pubmed: 35626163
J BUON. 2018 Jul-Aug;23(4):1130-1135
pubmed: 30358222
Carcinogenesis. 2004 Jun;25(6):973-8
pubmed: 14729580
Cell Mol Biol (Noisy-le-grand). 2016 Dec 30;62(14):38-43
pubmed: 28145855
Med Sci (Basel). 2020 Mar 13;8(1):
pubmed: 32183076
PLoS One. 2014 Jan 31;9(1):e87450
pubmed: 24498107
Sci Rep. 2021 Jul 23;11(1):15134
pubmed: 34302052
Mol Genet Genomic Med. 2018 Mar;6(2):268-275
pubmed: 29411539
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
J Biomed Biotechnol. 2012;2012:623019
pubmed: 22363173
Sci Total Environ. 2022 Oct 15;843:156965
pubmed: 35764155
PLoS One. 2014 Dec 29;9(12):e116027
pubmed: 25545243
Free Radic Biol Med. 2004 Mar 15;36(6):718-44
pubmed: 14990352
Antioxidants (Basel). 2017 Nov 03;6(4):
pubmed: 29099803
Oxid Med Cell Longev. 2019 May 5;2019:2730896
pubmed: 31191796
Cancer Lett. 2005 Nov 8;229(1):85-91
pubmed: 15946795
Med Oncol. 2012 Sep;29(3):1928-34
pubmed: 21904836
Oxid Med Cell Longev. 2016;2016:4197815
pubmed: 27781076
BMC Cancer. 2006 Aug 31;6:217
pubmed: 16945136
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
Tumour Biol. 2014 Jan;35(1):269-75
pubmed: 23975365
Am J Transl Res. 2014 Nov 22;6(6):649-63
pubmed: 25628777
Mol Cell Biol. 1990 May;10(5):2327-34
pubmed: 2183031
Cancer Cell. 2015 Feb 9;27(2):156-7
pubmed: 25670075
Expert Rev Clin Immunol. 2015 Feb;11(2):265-79
pubmed: 25391391
Biochim Biophys Acta. 2009 Nov;1790(11):1546-54
pubmed: 19289153
Free Radic Res. 2012 May;46(5):581-99
pubmed: 22257147
Free Radic Biol Med. 2010 Dec 1;49(11):1603-16
pubmed: 20840865
Tumour Biol. 2014 Feb;35(2):955-9
pubmed: 23990443
J Cancer Res Clin Oncol. 2011 Oct;137(10):1553-61
pubmed: 21842217
Int J Epidemiol. 2016 Jun;45(3):857-70
pubmed: 27097748
Indian J Clin Biochem. 2015 Jan;30(1):11-26
pubmed: 25646037
Cancer Lett. 2007 Mar 18;247(2):293-300
pubmed: 16797832
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):753-4
pubmed: 15767364
Clin Biochem. 2021 Jul;93:1-8
pubmed: 33773993
Biochim Biophys Acta. 2008 Nov;1780(11):1325-36
pubmed: 18206122
Oxid Med Cell Longev. 2014;2014:875861
pubmed: 25436036
ISRN Oncol. 2012;2012:137289
pubmed: 23119185
Int J Clin Exp Pathol. 2017 Sep 01;10(9):9527-9540
pubmed: 31966829
Exp Ther Med. 2014 Jan;7(1):171-178
pubmed: 24348785
Int J Mol Sci. 2017 Oct 22;18(10):
pubmed: 29065504
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Eur J Nutr. 2009 Sep;48(6):383-6
pubmed: 19415410
Medicina (Kaunas). 2019 Aug 03;55(8):
pubmed: 31382611
World J Urol. 2020 Aug;38(8):1895-1904
pubmed: 31676912
Cell Death Dis. 2017 Jan 19;8(1):e2562
pubmed: 28102840
Cancer Res. 2006 Mar 1;66(5):2844-52
pubmed: 16510607
PLoS One. 2016 Sep 29;11(9):e0163827
pubmed: 27684561
Anticancer Agents Med Chem. 2011 Feb;11(2):191-201
pubmed: 21434856

Auteurs

Predrag Nikic (P)

Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia.
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

Dejan Dragicevic (D)

Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia.
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

Djurdja Jerotic (D)

Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.

Slaviša Savic (S)

Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Department of Urology, KBC Dr. Dragiša Mišovic, 11000 Belgrade, Serbia.

Tatjana Djukic (T)

Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.

Branko Stankovic (B)

Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia.

Luka Kovacevic (L)

Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia.

Tatjana Simic (T)

Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.
Serbian Academy of Sciences and Arts, 11000 Belgrade, Serbia.

Marija Matic (M)

Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH